Fishel, et al. revealed that the use of a novel REDOX selective APE1 inhibitor in vitro and in vivo could effectively reduce the progression of bladder cancer, and the combination of this inhibitor with cisplatin, a commonly used chemotherapy drug, was more effective than cisplatin alone [26]. Here, APEX1 is linked to urinary bladder carcinoma.